Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson’s disease.


Exercise interventions in individuals with Parkinson’s disease incorporate goal-based motor skill training to engage cognitive circuitry important in motor learning. With this exercise approach, physical therapy helps with learning through instruction and feedback (reinforcement) and encouragement to perform beyond self-perceived capability. Individuals with Parkinson’s disease become more cognitively engaged with the practice and learning of movements and skills that were previously automatic and unconscious. Aerobic exercise, regarded as important for improvement of blood flow and facilitation of neuroplasticity in elderly people, might also have a role in improvement of behavioural function in individuals with Parkinson’s disease. Exercises that incorporate goal-based training and aerobic activity have the potential to improve both cognitive and automatic components of motor control in individuals with mild to moderate disease through experience-dependent neuroplasticity. Basic research in animal models of Parkinson’s disease is beginning to show exercise-induced neuroplastic effects at the level of synaptic connections and circuits.

Source: Lancet

 

Huntington’s disease: the road to progress.


Most clinicians carry, in their heads, roadmaps of the time course of the disorders they frequently treat. Drawn from experience with different patients over time, these composite roadmaps are useful for educating patients, designing possible rating scales, and providing a subjective way to assess treatment results. And, like a map of a planned journey, these mental constructs of disease course can identify predictable changes, such as road elevation, versus the unpredictable, such as changes in weather. In Huntington’s disease,1 for example, cognition slowly declines whereas psychiatric manifestations can flare or remit unexpectedly. But a clinician’s roadmap is far from perfect; it is unsuitable for the measurements and power calculations needed to test new treatments. Furthermore, these internal maps are subject to bias, not the least of which is a human tendency to assume change is linear and equal across all domains.

In this issue of The Lancet Neurology, Sarah Tabrizi and colleagues1 present the most recent findings from the TRACK-HD study, which was designed to create an unprecedentedly detailed map of changes in prodromal and early Huntington’s disease. About a decade ago, Sarah Tabrizi and colleagues began identifying promising instruments to measure change in this disorder that might be suitable for subsequent clinical trials.23 This task is possible because genetic testing allows investigators to identify undiagnosed Huntington’s disease gene carriers as those near to diagnosis and others who are likely to be diagnosed later. In TRACK-HD, the investigators assessed groups of such individuals yearly, along with diagnosed patients in early stages of the disease. The results have been at times disappointing, reassuring, surprising, and promising.4In the present report,1 Tabrizi and colleagues present findings from the final follow-up at 36 months from 298 participants: 97 control individuals, 58 participants with premanifest Huntington’s disease at least 10·8 years from disease onset, 46 with premanifest Huntington’s disease fewer than 10·8 years from disease onset, 66 with early Huntington’s disease and a total functional capacity score (TFC) of 11—13, and 31 with early Huntington’s disease and a TFC of 7—10.

Daring in scope, the study has taught us many things. It reassures us that we can indeed accurately track disease progression over time, using multiple measures, and it confirms our clinical experience in that psychiatric and behavioural problems, which, if untreated, contribute significantly to the burden of illness of Huntington’s disease, are unpredictable in their occurrence and severity. The finding that after 1 year and 2 years more variation in progression occurred than was anticipated was rather disappointing, but by extending the study to a third year, the aim of the study has been realised by the identification of various definitive landmarks of disease evolution.

Of the instruments used to measure disease progression, some are complex and costly, others portable and simple. Variations in finger tapping and motor persistence have proven to be surprisingly simple yet accurate markers for disease progression or diagnosis. At the more complex end, MRI provides various robust markers of disease evolution. The rate of change in imaging biomarkers varies; it tends to accelerate with disease progression particularly after the critical point of phenoconversion, going from undiagnosed to diagnosed Huntington’s disease. As an endpoint, phenoconversion is rather elusive, as reported in other studies.5 Perhaps the need for tact exceeds the need for rigor in timing of the diagnosis because of its irreversible implications for patients and their families. Nonetheless, in TRACK-HD, making a diagnosis of Huntington’s disease seems to be associated with some type of crucial inflection point in progression, possibly signifying the onset of intracellular cascades beyond the accumulation of misfolded proteins.

The number of investigators who have contributed, directly or indirectly, to the conceptualisation and undertaking of TRACK-HD is substantial. This report itself summarises a vast amount of work and includes a substantial appendix of additional information and data. The TRACK-HD team should be praised for this bold article, which tests the limits of what might be considered a maximum publishable unit in neurology.

Hippocrates is generally credited with recognising the importance of the timeline of disease evolution epitomised by the objective recording of daily findings and methods and terms such as chronicity, exacerbation, paroxysm, and crisis. Sarah Tabrizi’s team has provided a modernised and extended example of this practice, one that sets the standard for observational studies in other neurodegenerative diseases. Virtual roadmaps of disease in the minds of practitioners6 are good for care in the framework of the traditional patient encounter, but it takes substantial effort, teamwork, and genius to turn them into rigorous, quantifiable timelines that can be used to test efficacy in future therapeutic trials.

Source: Lancet

 

Impact of global cerebral atrophy on clinical outcome after subarachnoid hemorrhage.


Abstract

OBJECT

Atrophy in specific brain areas correlates with poor neuropsychological outcome after subarachnoid hemorrhage (SAH). Few studies have compared global atrophy in SAH with outcome. The authors examined the relationship between global brain atrophy, clinical factors, and outcome after SAH.

METHODS

This study was a post hoc exploratory analysis of the Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1) trial, a randomized, double-blind, placebo-controlled trial of 413 patients with aneurysmal SAH. Patients with infarctions or areas of encephalomalacia on CT, and those with large clip/coil artifacts, were excluded. The 97 remaining patients underwent CT at baseline and 6 weeks, which was analyzed using voxel-based volumetric measurements. The percentage difference in volume between time points was compared against clinical variables. The relationship with clinical outcome was modeled using univariate and multivariate analysis.

RESULTS

Older age, male sex, and systemic inflammatory response syndrome (SIRS) during intensive care stay were significantly associated with brain atrophy. Greater brain atrophy was significantly associated with poor outcome on the modified Rankin scale (mRS), severity of deficits on the National Institutes of Health Stroke Scale (NIHSS), worse executive functioning, and lower EuroQol Group–5D (EQ-5D) score. Adjusted for confounders, brain atrophy was not significantly associated with Mini-Mental State Examination and Functional Status Examination scores. Brain atrophy was not associated with angiographic vasospasm or delayed ischemic neurological deficit.

CONCLUSIONS

Worse mRS score, NIHSS score, executive functioning, and EQ-5D scores were associated with greater brain atrophy and older age, male sex, and SIRS burden. These data suggest outcome is associated with factors that cause global brain injury independent of focal brain injury.

Source: JNS

 

 

Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study.


Background

Extracranial arterial dilatation has been hypothesised to be the cause of pain in patients who have migraine without aura. To test that hypothesis, we aimed to measure extracranial and intracranial arteries during attacks of migraine without aura.

Methods

In this cross-sectional study, we recruited patients aged 18—60 years from the Danish Headache Centre and via announcements on a Danish website. We did magnetic resonance angiography during spontaneous unilateral migraine attacks. Primary endpoints were difference in circumference of extracranial and intracranial arterial segments comparing attack and attack-free days and the pain and the non-pain side. The extracranial arterial segments measured were the external carotid (ECA), the superficial temporal (STA), the middle meningeal (MMA), and the cervical part of the internal carotid (ICAcervical) arteries. The intracranial arterial segments were the cavernous (ICAcavernous) and cerebral (ICAcerebral) parts of the internal carotid, the middle cerebral (MCA), and the basilar (BA) arteries. This study is registered atClinicaltrials.gov, number NCT01471314.

Findings

Between Oct 12, 2010, and Feb 8, 2012, we recruited 78 patients, of whom 19 women had a scan during migraine and were included in the final analysis. On migraine compared with non-migraine days, we detected no statistically significant dilatation of the extracranial arteries on the pain side (ECA, mean difference 1·2% [95% CI −5·7 to 8·2] p=0·985, STA 3·6% [—3·7 to 11·0] p=0·532, MMA 1·7% [—1·7 to 5·2] p=0·341, and ICAcervical 2·3% [—0·3 to 4·9] p=0·093); the intracranial arteries were more dilated during attacks (MCA, 13·0% [6·4 to 19·6] p=0·001, ICAcerebral 11·5% [5·6 to 17·3] p=0·0004, and ICAcavernous 11·4% [5·3 to 17·5] p=0·001), except for the BA (1·6% [—2·7 to 5·9] p=0·621). Compared with the non-pain side, during attacks we detected dilatation on the pain side of the intracranial arteries (MCA, mean difference 10·5% [0·7—20·3] p=0·044, ICAcerebral (14·4% [4·6—24·1] p=0·013), and ICAcavernous (9·1% [3·9—14·4] p=0·003) but not of the extracranial arteries (ECA, 2·1% [—3·8 to 9·2] p=0·238, STA, 3·6% [—3·7 to 10·8] p=0·525, MMA, 2·7% [—1·3 to 5·6] p=0·531, and ICAcervical, 5·0% [—0·5 to 10·4] p=0·119).

Interpretation

Migraine pain was not accompanied by extracranial arterial dilatation, and by only slight intracranial dilatation. Future migraine research should focus on the peripheral and central pain pathways rather than simple arterial dilatation.

Source: Lancet

 

Angiostrongylus meningoencephalitis: survival from minimally conscious state to rehabilitation.


The nematode Angiostrongylus cantonensis has spread down the eastern coast of Australia over recent decades. A healthy 21-year-old man developed life-threatening eosinophilic meningoencephalitis following ingestion of a slug in Sydney. We describe the first case of this severity in which the patient survived.

Clinical record

A 21-year-old man presented with a 3-day history of insomnia and paraesthesia affecting his lower limbs bilaterally. He had no associated headache, meningism or fever. He was previously well with no significant medical history.

On admission, he had begun to develop progressive weakness of his lower limbs associated with pain and dysaesthesia. A full blood count showed a total white cell count of 10.6 × 109/L (reference interval [RI], 4.0–11.0 × 109/L) with mild eosinophilia (0.5 × 109/L [RI, < 0.4 × 109/L]). Magnetic resonance imaging (MRI) scans of his brain and spine showed no abnormality. His cerebrospinal fluid (CSF) was acellular, with normal glucose and protein levels.

A provisional diagnosis of Guillain–Barré syndrome was made and the patient was treated with a 5-day course of intravenous immunoglobulin. Over 1 week he developed evidence of autonomic instability with urinary retention, fluctuating sinus tachycardia and hypertension, and a paralytic ileus. By the second week of hospitalisation he had developed hallucinations and a fluctuating level of consciousness.

A repeat CSF sample revealed a raised protein level of 1.20 g/L (RI, 0.15–0.45 g/L), a low glucose level of 2.3 mmol/L (RI, 2.5–5.6 mmol/L), with 2 × 109/L red cells (RI, < 5 × 109/L), 406 × 109/L mononuclear cells (RI, < 5 × 109/L), and 30 × 109/L polymorphs (RI, nil). The opening pressure was elevated at 31 cm H2O (RI, 6–20 cm H2O). He was commenced on empirical antibiotic and antiviral treatment, with intravenous hydrocortisone (100 mg four times daily) to cover the possibility of a steroid-responsive encephalopathy. An electroencephalogram was consistent with generalised encephalopathy without focal epileptiform activity. CSF bacterial cultures, cryptococcal antigen testing and polymerase chain reaction testing for herpes simplex virus and enterovirus were negative. HIV serological testing was negative. The patient’s condition continued to deteriorate, with a declining level of consciousness, progressive quadriparesis and respiratory failure necessitating endotracheal intubation and mechanical ventilation on Day 12 after admission.

Progress computed tomography (CT) brain imaging results remained normal. His peripheral eosinophil count had risen, later peaking at 1.9 × 109/L on Day 24. A third lumbar puncture was performed. His CSF protein remained elevated at 0.71g/L, CSF red cell count was 216 × 109/L and CSF white cell count was 504 × 109/L. Specific staining for eosinophils was performed, showing 37% of the leukocytes to be eosinophils (RI, < 10%,Box 1).

By this stage it had emerged that the patient had eaten a slug from a Sydney garden, as a dare, 7 days before presentation. An enzyme immunoassay for Angiostrongylus IgG performed on the CSF was positive. A progress MRI scan, performed on Day 26 after admission, revealed multiple foci of hyperintensity in the cerebral hemispheres, brainstem and cerebellum as well as within the spinal cord (Box 2). Several of the lesions showed restricted diffusion and some showed contrast enhancement. Pial enhancement was seen within the posterior fossa and over the spinal cord.

Treatment with high-dose corticosteroids was continued but the patient’s condition continued to decline. An unresponsive state developed, with flaccid tone in all four limbs and the loss of brainstem reflexes. Given the severity of the patient’s condition, a trial of albendazole 400 mg twice daily was given, with continued corticosteroid cover (dexamethasone 4 mg intravenously four times daily) and he remained on this treatment for 1 month. There was no change in his condition and he remained supported by mechanical ventilation via a tracheostomy in a minimally conscious state for 8 months.

During this time, there was much discussion between the patient’s family and treating doctors about his prognosis and probable outcome. Treatment was continued on the basis of his age and the uncertainty of the natural history of this rare disease. His clinical course was complicated by hydrocephalus requiring a ventriculoperitoneal shunt, recurrent episodes of ventilator-associated pneumonia, and seizures that were difficult to control despite multiple antiepileptic drugs. After 13 months, there was a very slow improvement in his level of consciousness, such that a slow weaning of respiratory support could be attempted. He could successfully maintain his own ventilation during the day (though with an ataxic respiratory pattern), but remained dependent on nocturnal mechanical ventilation.

The patient was discharged to the ward from intensive care in the 15th month of admission, where he continued to make slow but definite progress. There was gradual recovery of some distal power in his upper and lower limbs and he developed the ability to communicate with head movements. He was discharged to a rehabilitation facility 22 months after admission, where there has been ongoing gradual improvement. He now has antigravity power in his limbs and is capable of more complex non-verbal communication.

Discussion

Angiostrongylus cantonensis, also known as the rat lungworm, is the most common cause of eosinophilic meningitis globally. This condition generally follows a benign, self-limited course.1 Rarely, the parasite causes meningoencephalitis, which should be considered a related but distinct clinical entity with a dramatically poorer prognosis. The mortality rate has been reported at 79%2 and, of patients who become comatose, at least 90% do not survive.3

A. cantonensis is endemic in South-East Asia and the Pacific region, and has spread down the eastern coast of Australia over the past 50 years.4 In Australia, it has been observed that cases tend to be particularly severe. This reflects the higher total larval load ingested from terrestrial hosts, which feed on rat faecal pellets harbouring thousands of larvae. In comparison, aquatic snails, which commonly cause the disease in South-East Asia, generally carry a smaller larval load.5,6 The first reported human case acquired in Sydney occurred in 2001,7 in the remarkably similar circumstances of a young man accepting a dare to eat a slug, highlighting the importance of specific questioning in the patient’s history. Our patient’s case is only the second reported case acquired in Sydney and, internationally, our patient is the first with the disease of this severity to have survived.

Recent investigations have sought to identify factors associated with the development of clinically severe angiostrongyliasis. In one study, clinical features including headache, abnormal CSF pressure and abnormal peripheral blood eosinophil count were associated with severe disease.8 An Activation Criteria for Angiostrongyliasis (ACA) scoring system, incorporating these factors, was proposed and validated in a population of Chinese patients, with a score of ≥ 7 predictive of severe disease. If we had used the presenting eosinophil count, our patient would only have had an ACA score maximum of 5, and most likely lower than this if his CSF opening pressure had been recorded at the first lumbar puncture. He would have scored 8 if his peak peripheral eosinophil count and his highest recorded CSF pressure had been used.

A second study investigated factors specifically associated with the development of the encephalitic form of the disease.2 In a cohort of 94 patients with angiostrongyliasis, of whom 14 developed encephalitis, it was found that the clinical factors predictive of encephalitis were temperature > 38°C at presentation, older age and longer duration of headache. Fever at presentation was associated with a remarkable 37-fold risk of encephalitis. Interestingly, other variables such as CSF opening pressure, peripheral or CSF eosinophil counts or paraesthesia were not predictive of encephalitis in this study. Our case indicates that caution should be used when applying the predictive factors reported in these studies, and suggests that peak eosinophil count and delayed CSF pressure results may be more useful when calculating the ACA.

The initial difficulty with diagnosis in this case emphasises the need for clinical suspicion of this condition in the setting of acute-onset neurological symptoms and peripheral eosinophilia in endemic areas, including the eastern coast of Australia. It is essential to seek a history of consuming raw or undercooked food, and specifically any ingestion of molluscs. The case illustrates the importance of repeat CSF examination if the diagnosis is suspected and the initial CSF test results are negative. It also highlights the need to request specific CSF examination to ensure any eosinophils are not mistaken for neutrophils.

The optimal treatment for Angiostrongylus meningoencephalitis remains poorly defined. Corticosteroids are commonly used, with the rationale of dampening the inflammatory reaction to the nematode, and have been shown in a double-blind, placebo-controlled trial to provide symptomatic relief in eosinophilic meningitis.9 However, studies of patients with the encephalitic form of the disease have not found corticosteroids to be effective.3 Anthelmintics are generally not used due to the theoretical possibility of exacerbating cerebral inflammation and damage as a result of larval death in the central nervous system (CNS), and the lack of evidence of their efficacy.9,10 We used albendazole when there was little to lose and, perhaps as expected, it did not lead to any appreciable benefit. In the absence of effective treatment of angiostrongyliasis, it is important in endemic areas that the public understand the small but very serious risks associated with ingestion of uncooked molluscs.

It is known that time spent in a minimally conscious state following traumatic brain injury does not correlate with the chance of functional recovery.11 This observation may extend to patients with diffuse brain injury caused by severe cerebral infection or inflammation. This case shows the potential for the CNS to recover following a severe, generalised insult in a young patient with supportive care. It is important for doctors to appreciate this capacity when wrestling with difficult decisions about continuation of care for critically unwell patients.

Source: MJA

Stroke patients with cerebral microbleeds on MRI scans have arteriolosclerosis as well as systemic atherosclerosis.


Cerebral microbleeds (CMBs) are recognized as a manifestation of arteriolosclerosis in cerebral small vessels. However, little is known regarding whether stroke patients with CMBs often have systemic atherosclerosis. The aim of the present study was to elucidate this issue using the cardio–ankle vascular index (CAVI), a new index of systemic atherosclerosis, in acute ischemic stroke patients. We prospectively studied 105 patients (71 males, median age=70.0 years) with acute ischemic stroke. All of the patients were examined using T2*-weighted gradient echo magnetic resonance imaging (MRI) to look for and assess the CMBs and using fluid-attenuated inversion recovery to evaluate white matter hyperintensity (WMH). We assigned the patients into CMB and non-CMB groups and compared the clinical characteristics of these groups. The factors associated with CMBs were investigated using multivariate logistic regression analysis. T2*-weighted gradient echo MRI revealed CMBs in 47 patients (44.8%) and no CMBs in 58 patients (55.2%). The CAVI was significantly higher in the CMBs group (10.5 vs. 8.6, P<0.001). In the multivariate logistic regression analysis, CAVI per one point increase (odds ratio (OR), 1.50; 95% confidence interval (CI), 1.12–2.00; P=0.006), advanced WMH (OR, 4.78; 95% CI, 1.55–14.74; P=0.006) and impaired kidney function (OR, 3.31; 95% CI, 1.16–9.81; P=0.031) were independent factors associated with the presence of CMBs. A high CAVI was independently associated with CMBs in patients with acute ischemic stroke. Our results indicated that ischemic stroke patients with CMBs may have cerebral arteriolosclerosis as well as systemic atherosclerosis.

Source: Hypertension Research/nature.

The misapplication of the term spinal cord injury without radiographic abnormality (SCIWORA) in adults.


Como JJ et al. – Spinal cord injury without computed tomography evidence of trauma (SCIWOCTET) is mainly a disease of adults, and its subset Spinal cord injury without radiographic abnormality (SCIWORA), a disease of children, is much less common. Adults with this disease have computed tomographic (CT) scans showing canal stenosis and significant degenerative changes in the cervical spine; thus, it is not accurate to state that they have SCIWORA. The characteristics of this patient population are important as SCIWOCTET is the concern when clearing the cervical spines of trauma patients with a CT scan of the cervical spine negative for injury.

Source: Journal of Trauma

 

 

 

Withdrawal of Life Support and Stroke Mortality.


A review of stroke deaths at one hospital highlights the substantial effect that family decisions about life support have on stroke mortality.

Stroke mortality is being considered in models to measure quality of care in hospitals. Some evidence suggests that unmeasured factors such as stroke severity can affect mortality (JW Neurol Aug 7 2012). Now, researchers have examined the effect that withdrawal of life-sustaining treatments has on short-term stroke mortality, by investigating the 37 stroke deaths that occurred at one hospital or during postdischarge hospice care in 2009.

Of the 37 deaths, 36 occurred after avoidance or withdrawal of life support, based on the patient’s or family’s decision. Three neurologists at the center who were not otherwise involved in the study judged that about 40% of these short-term deaths might have been avoided if life support had been used or continued for patients with borderline or better prospects for survival (4.6% mortality vs. 7.8%). Care of these patients adhered to 98% of four standard-of-care measures.

The Editors

Comment: Vascular neurologists have traditionally been wary of the value of acute stroke mortality as a quality measure. Because aggressive care can sometimes result in patients surviving the acute (30-day poststroke) period, but with severe disability, would the result be acceptable to patients and their families?

This study demonstrates the impact that clinician decisions about withdrawal of care have on stroke mortality. The vast majority of deaths after ischemic stroke were caused by withdrawal of mechanical ventilation or artificial nutrition methods, not by deviations from standard care metrics. The authors do not comment on the proportion of patients that underwent hemicraniectomy, a procedure with proven value for reducing stroke mortality. In an era of finite healthcare resources, one hopes that hospitals will not pursue hyperaggressive care just to make sure that the 30-day stroke mortality appears low.

Source: Journal Watch Neurology